This event is not part of the official ACC Annual Scientific Session and/or the ACC’s Innovation in Intervention: i2 Summit in Partnership with the Cardiovascular Research Foundation, as planned by their Program Committees |
|
Cardiovascular health professionals face an ever increasing complexity of diagnostic and therapeutic dilemmas that require a comprehensive understanding of risk based management.
This symposium will address common challenges in clinical cardiology and provide attendees with practical solutions based on innovative approaches including complexity and significance of right versus left heart diseases.
The clinical appeal of the program will also be based on case-based interactive component using ARS that will facilitate assimilation of new ideas and risk stratification into practice.
 |
 |
 |
 |
 |
| Home |
Agenda |
Registration |
Faculty |
Contact Us |
| Upon completion of this activity, participants should be better able to: |
| 1. |
Identify how lessons from our understanding of multimechanistic pathophysiology and multitargeted therapeutic approaches in heart failure might apply in managing the cardiopulmonary complications of PAH. |
| 2. |
Apply an evidence-based approach to diagnosis of PAH and PH secondary to heart failure, with a focus on echocardiography, vasodilator testing, and right heart catheterization. |
| 3. |
Review the utilization of right heart catheterization parameters for the diagnosis of pulmonary arterial hypertension. |
| 4. |
Screen and confirm a diagnosis of pulmonary arterial hypertension according to current best practice. |
| 5. |
Identify pathogenic mediators of PAH, with a focus on the endothelin and prostacyclin pathways and appraise implications in terms of treatment targets. |
| 6. |
Employ state-of-the-art evidence-based treatment algorithms to optimize parenteral and oral therapies and assess implications of emerging clinical data for future management plans. |
| 7. |
Recognize genetic variants that are associated with greater CV risk and illustrate when to consider genetic testing to assess CVD risk. |
| 8. |
Use serum biomarkers in patients with left and right heart diseases for optimal patient outcomes. |
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the Foundation for Medical Education and Research. PIM is accredited by the ACCME to provide continuing medical education for physicians. |
Credit Designation:
Postgraduate Institute for Medicine (PIM) designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. |
Target Audience:
This activity has been designed to meet the educational needs of cardiologists and internists involved in the care of patients with cardiovascular disease and pulmonary arterial hypertension. |
 |
Americans with Disabilities Act:
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Gail Karaim prior to the live event via email at karaimg@mdprimer.com. |
|
|
